The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kholodova N.B.

Ponkratova Iu.A.

Rossiĭskiĭ nauchnyĭ tsentr rentgenoradiologii Minzdrava RF, Moskva

Sinkin M.V.

N.V. Sklifosovsky First Aid Scientific Research Institute, Moscow, Russia

Clinical and electromyography characteristics of chemotherapy-induced polyneuropathy

Authors:

Kholodova N.B., Ponkratova Iu.A., Sinkin M.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9): 59‑66

DOI: 10.17116/jnevro20171179159-66

Read: 2790 times

Contact the author
Table of contents

CLINICAL AND ELECTROMYOGRAPHY CHARACTERISTICS OF CHEMOTHERAPY-INDUCED POLYNEUROPATHY
CLINICAL AND ELECTROMYOGRAPHY CHARACTERISTICS OF CHEMOTHERAPY-INDUCED POLYNEUROPATHY

To cite this article:

Kholodova NB, Ponkratova IuA, Sinkin MV. Clinical and electromyography characteristics of chemotherapy-induced polyneuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9):59‑66. (In Russ.)
https://doi.org/10.17116/jnevro20171179159-66

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Clinical and instrumental diagnostics of facial neuropathy in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):31-36
Coca­rnit in complex therapy of diabetic peri­pheral poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):73-81
Role of actin/actin-binding proteins in extracellular vesi­cles in mechanisms of tumor progression and deve­lopment of drug-induced poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(3):7-12
Myoclonus in Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(4-2):63-69
Systemic toxi­city of local anesthetics. Clinical guidelines of the All-Russian public orga­nization «Federation of anesthesiologists and reanimatologists». Russian Journal of Anesthesiology and Reanimatology. 2025;(5):8-21
Characteristics of the functional state of the masticatory muscles in patients with hemi­facial microsomy at the stages of complex treatment. Stomatology. 2025;(5):29-36
Electromyographic evaluation of the dyna­mic electroneurostimulation effe­ctiveness in skeletal class III patient reha­bilitation after orthognathic surgery. Stomatology. 2025;(6):43-48
Abstract:

Objective. The study aimed at determining clinical and electromyography characteristics and developing the methods of CIPN treatment. Material and methods. A clinical and electromyographic examinations and treatment of 30 with CIPN symptoms developed after polychemotherapy were performed. The authors developed treatment schemes included allopathic, homeopathic drugs, hydrotherapy and pharmacopuncture. Results and conclusion. Most of the patients were diagnosed with axonal polyneuropathy with affection of long nerves of the limbs, some patients had a combination of axonopathy with myelopathy. After treatment, regression of neuropathy symptoms and improvement of quality of life was noted in all patients.

Keywords:

complications of polychemotherapy
neurotoxicity
chemotherapy-induced peripheral neuropathy (CIPN)
electromyography

Authors:

Kholodova N.B.

Ponkratova Iu.A.

Rossiĭskiĭ nauchnyĭ tsentr rentgenoradiologii Minzdrava RF, Moskva

Sinkin M.V.

N.V. Sklifosovsky First Aid Scientific Research Institute, Moscow, Russia

Close metadata

References:

  1. Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. European Journal of Cancer. 2002;38(14):1832-1837. https://doi.org/10.1016/S0959-8049(02)00229-0
  2. Cavaletti G, Frigen B, Lanzani F, Mattavell L, Susani E, Alberti P, Cortinovis D, Bidoli P. Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools. European Journal of Cancer. 2010;46(3):479-494. https://doi.org/10.1016/j.ejca.2009.12.008
  3. Cavaletti G, Cornblath D, Merkies I, Postma T, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou A, Kalofonos H, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber C, Lalisang R, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi M, Mazzeo A, Pace A, Pessino A, Schenone A, Toscano A, Argyriou A, Brouwer B, Frigeni B, Piras B, Briani C, Dalla Torre C, Dominguez Gonzalez C, Faber C, Tomasello C, Binda D, Brandsma D, Cortinovis D, Psimaras D, Ricard D, Storey D, Cornblath D, Galie E, Lindeck Pozza E, Rossi E, Vanhoutte E, Lanzani F, Pastorelli F, Altavilla G, Cavaletti G, Granata G, Kalofonos H, Ghignotti I, Merkies I, Bruna J, Hense J, Heimans J, Mattavelli L, Padua L, Reni L, Bakkers M, Boogerd M, Campagnolo M, Cazzaniga M, Eurelings M, Leandri M, Lucchetta M, Penas Prado M, Russo M, Valsecchi M, Piatti M, Alberti P, Bidoli P, Grant R, Plasmati R, Velasco R, Lalisang R, Meijer R, Fabbri S, Dorsey S, Galimberti S, Kerrigan S, Koeppen S, Postma T, Boogerd W, Grisold W. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Annals of Oncology. 2012;24(2):454-462. https://doi.org/10.1093/annonc/mds329
  4. Hausheer F, Schilsky R, Bain S, Berghorn E, Lieberman F. Diagnosis, Management and Evaluation of Chemotherapy-Induced Peripheral Neuropathy. Seminars in Oncology. 2006;33(1):15-49. https://doi.org/10.1053/j.seminoncol.2005.12.010
  5. Schneider B, Li L, Radovich M, Shen F, Miller K, Flockhart D, Jiang G, Vance G, Gardner L, Vatta M, Bai S, Lai D, Koller D, Zhao F, O’Neill A, Smith M, Railey E, White C, Partridge A, Sparano J, Davidson N, Foroud T, Sledge G. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clinical Cancer Research. 2015;21(22):5082-5091. https://doi.org/10.1158/1078-0432.ccr-15-0586
  6. Argyriou A, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Critical Reviews in Oncology/Hematology. 2012;82(1):51-77. https://doi.org/10.1016/j.critrevonc.2011.04.012
  7. Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2011;18(1):132-138. https://doi.org/10.1007/s10147-011-0352-x
  8. Scripture C, Figg W, Sparreboom A. Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives. Current Neuropharmacology. 2006;4(2):165-172. https://doi.org/10.2174/157015906776359568
  9. Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, Febbraro A, Marinaccio M, Vernaglia Lombardi A, Manzione L, Cartenì G, Nardi M, Danese S, Valerio M, de Matteis A, Massidda B, Gasparini G, Di Maio M, Pisano C, Perrone F. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer. 2006;6(1). https://doi.org/10.1186/1471-2407-6-5
  10. Allen D, Kiernan J. Permeation of proteins from the blood into peripheral nerves and ganglia. Neuroscience. 1994;59(3):755-764. https://doi.org/10.1016/0306-4522(94)90192-9
  11. Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, Stewart DJ. Cisplatin neurotoxicity: the relationshipbetween dosage, time, andplatinum concentrationin neurologic tissues, and morphologicevidence of toxicity. J Clin Oncol. 1992;10:795-803.
  12. Krarup-Hansen, Rietz, Krarup, Heydorn, Rorth, Schmalbruch. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol. 1999;25(1):28-39. https://doi.org/10.1046/j.1365-2990.1999.00160.x
  13. Ta L, Espeset L, Podratz J, Windebank A. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum — DNA binding. NeuroToxicology. 2006;27(6):992-1002. https://doi.org/10.1016/j.neuro.2006.04.010
  14. Dzagnidze A, Katsarava Z, Makhalova J, Liedert B, Yoon M, Kaube H, Limmroth V, Thomale J. Repair Capacity for Platinum-DNA Adducts Determines the Severity of Cisplatin-Induced Peripheral Neuropathy. Journal of Neuroscience. 2007;27(35):9451-9457. https://doi.org/10.1523/jneurosci.0523-07.2007
  15. Peters C, Jimenez-Andrade J, Kuskowski M, Ghilardi J and Mantyh P. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Research. 2007;1168:46-59. https://doi.org/10.1016/j.brainres.2007.06.066
  16. Topp K, Tanner K and Levine J. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. The Journal of Comparative Neurology. 2000;424(4):563-576. https://doi.org/10.1002/1096-9861(20000904)424:4<563::aid-cne1>3.0.co;2-u
  17. Giannini F, Volpi N, Rossi S, Passero S, Fimiani M and Cerase A. Thalidomide-induced neuropathy: A ganglionopathy? Neurology. 2003;60(5):877-878. https://doi.org/10.1212/01.wnl.0000049462.03800.b1
  18. Casafont I, Berciano M and Lafarga M. Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons. Neurotoxicity Research. 2009;17(2):167-178. https://doi.org/10.1007/s12640-009-9086-1
  19. Theiss C and Meller K. Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell and Tissue Research. 2000;299(2):213-224. https://doi.org/10.1007/s004410050019
  20. LaPointe N, Morfini G, Brady S, Feinstein S, Wilson L, Jordan M. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: Implications for chemotherapy-induced peripheral neuropathy. NeuroToxicology. 2013;37:231-239. https://doi.org/10.1016/j.neuro.2013.05.008
  21. Poruchynsky M, Sackett D, Robey R, Ward Y, Annunziata C, Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle. 2008;7(7):940-949. https://doi.org/10.4161/cc.7.7.5625
  22. Flatters S, Bennett G. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction. Pain. 2006;122(3):245-257. https://doi.org/10.1016/j.pain.2006.01.037
  23. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D’Incalci M, De Coster R. Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. Experimental Neurology. 2007;204(1):317-325. https://doi.org/10.1016/j.expneurol.2006.11.010
  24. Kirchmair R, Tietz A, Panagiotou E, Walter D, Silver M, Yoon Y, Schratzberger P, Weber A, Kusano K, Weinberg D, Roppe, A, Isner J, Losordo D. Therapeutic Angiogenesis Inhibits or Rescues Chemotherapy-induced Peripheral Neuropathy: Taxol- and Thalidomide-induced Injury of Vasa Nervorum is Ameliorated by VEGF. Molecular Therapy. 2007;15(1):69-75. https://doi.org/10.1038/sj.mt.6300019
  25. Melli G, Jack C, Lambrinos G, Ringkamp M, Höke A. Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiology of Disease. 2006;24(3):525-530. https://doi.org/10.1016/j.nbd.2006.08.014
  26. Silva A, Wang Q, Wang M, Ravula S, Glass J. Evidence for direct axonal toxicity in vincristine neuropathy. Journal of the Peripheral Nervous System. 2006;11(3):211-216. https://doi.org/10.1111/j.1529-8027.2006.0090.x
  27. Isoardo G, Bergui M, Durelli L, Barbero P, Boccadoro M, Bertola A, Ciaramitaro P, Palumbo A, Bergamasco B, Cocito D. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurologica Scandinavica. 2004;109(3):188-193. https://doi.org/10.1034/j.1600-0404.2003.00203.x
  28. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons. European Journal of Pharmacology. 2000;406(1):25-32. https://doi.org/10.1016/s0014-2999(00)00667-1
  29. Webster R, Brain K, Wilson R, Grem J, Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. British Journal of Pharmacology. 2005;146(7):1027-1039. https://doi.org/10.1038/sj.bjp.0706407
  30. Sittl R, Lampert A, Huth T, Schuy E, Link A, Fleckenstein J, Alzheimer C, Grafe P, Carr, R. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current. Proceedings of the National Academy of Sciences. 2012;109(17):6704-6709. https://doi.org/10.1073/pnas.1118058109
  31. Quasthoff S, Hartung H. Chemotherapy-induced peripheral neuropathy. Journal of Neurology. 2002;249(1):9-17. https://doi.org/10.1007/pl00007853
  32. Park S, Goldstein D, Krishnan A, Lin C, Friedlander M, Cassidy J, Koltzenburg M, Kiernan M. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA: A Cancer Journal for Clinicians. 2013;63(6):419-437. https://doi.org/10.3322/caac.21204
  33. Griffith K, Merkies I, Hill E, Cornblath D. Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. Journal of the Peripheral Nervous System. 2010;15(4):314-325. https://doi.org/10.1111/j.1529-8027.2010.00292.x
  34. Fromme E. How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30. Journal of Clinical Oncology. 2004;22(17):3485-3490. https://doi.org/10.1200/jco.2004.03.025
  35. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris M, Scher H, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. The Lancet Oncology. 2006;7(11):903-909. https://doi.org/10.1016/s1470-2045(06)70910-x
  36. Cornblath D, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T. Total neuropathy score: Validation and reliability study. Neurology. 1999;53(8):1660-1660. https://doi.org/10.1212/wnl.53.8.1660
  37. Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, Cocito D, Padua L, Ghiglione E, Manicone M, Giussani G.. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System. 2006;11(2):135-141. https://doi.org/10.1111/j.1085-9489.2006.00078.x
  38. Postma T, Aaronson N, Heimans J, Muller M, Hildebrand J, Delattre J, Hoang-Xuan K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer. 2005;41(8):1135-1139. https://doi.org/10.1016/j.ejca.2005.02.012
  39. Calhoun E, Welshman E, Chang C, Lurain J, Fishman D, Hunt T, Cella D. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. International Journal of Gynecological Cancer. 2003;13(6):741-748. https://doi.org/10.1111/j.1525-1438.2003.13603.x
  40. Hershman D, Weimer L, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew K. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Research and Treatment. 2010;125(3):767-774. https://doi.org/10.1007/s10549-010-1278-0
  41. Huang H, Brady M, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. International Journal of Gynecological Cancer. 2007;17(2):387-393. https://doi.org/10.1111/j.1525-1438.2007.00794.x
  42. Sasane M, Tencer T, French A, Maro T, Beusterien K. Patient-Reported Outcomes in Chemotherapy-Induced Peripheral Neuropathy: A Review. The Journal of Supportive Oncology. 2010;8(6):15-21. https://doi.org/10.1016/j.suponc.2010.09.029
  43. Park S, Lin C, Krishnan A, Goldstein D, Friedlander M, Kiernan M. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009;132(10):2712-2723. https://doi.org/10.1093/brain/awp219
  44. Chaudhry V, Rowinsky E, Sartorius S, Donehower R, Cornblath D. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Annals of Neurology. 1994;35(3):304-311. https://doi.org/10.1002/ana.410350310
  45. LoMonaco M, Milone M, Batocchi A, Padua L, Restuccia D, Tonali P. Cisplatin neuropathy: clinical course and neurophysiological findings. Journal of Neurology. 1992;239(4):199-204. https://doi.org/10.1007/bf00839140
  46. Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C. Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up. European Neurology. 2006;56(1):13-16. https://doi.org/10.1159/000094376
  47. Lehky T, Leonard G, Wilson R, Grem J, Floeter M. Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy. Muscle & Nerve. 2004;29(3):387-392. https://doi.org/10.1002/mus.10559
  48. Kuwabara S, Dispenzieri A, Arimura K, Misawa S, Nakaseko C. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M‐protein, and skin changes) syndrome. Cochrane Database of Systematic Reviews. 2012;6:CD006828. https://doi.org/10.1002/14651858.CD006828
  49. Viala K, Behin A, Maisonobe T, Leger J, Stojkovic T, Davi F, Leblond V, Bouche P. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? Journal of Neurology, Neurosurgery & Psychiatry. 2008;79(7):778-782. https://doi.org/10.1136/jnnp.2007.125930
  50. Klein C, Moon J, Mauermann M, Zeldenrust S, Wu Y, Dispenzieri A, Dyck P. The Neuropathies of Waldenström’s Macroglobulinemia (WM) and IgM-MGUS. Can J Neurol Sci. 2011;38(02):289-295. https://doi.org/10.1017/s0317167100011483
  51. Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicitiesin testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med. 2007;5:70. https://doi.org/10.1186/1479-5876-5-70
  52. Marsh S, Paul J, King C, Gifford G, McLeod H, Brown R. Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer. Journal of Clinical Oncology. 2007;25(29):4528-4535. https://doi.org/10.1200/jco.2006.10.4752
  53. Bergmann T, Gréen H, Brasch-Andersen C, Mirza M, Herrstedt J, Hølund, B du Bois A, Damkier P, Vach W, Brosen K, Peterson, C. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. European Journal of Clinical Pharmacology. 2011;67(7):693-700. https://doi.org/10.1007/s00228-011-1007-6
  54. Dennison JB, Jones DR, Renbarger JL,Hall SD. Effect of CYP3A5 expression onvincristine metabolism with human livermicrosomes. J Pharmacol Exp Ther. 2007;321:553-563. https://doi.org/10.1124/jpet.106.118471
  55. Won H, Lee J, Park J, Park Y, Lim H, Kang W, Kim J, Lee S, Park S. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2011;118(11):2828-2836. https://doi.org/10.1002/cncr.26614
  56. Johnson D, Corthals S, Walker B, Ross F, Gregory W, Dickens N, Lokhorst H, Goldschmidt H, Davies F, Durie, B Van Ness B, Child J, Sonneveld P, Morgan G. Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma. Journal of Clinical Oncology. 2011;29(7):797-804. https://doi.org/i:10.1200/jco.2010.28.0792
  57. Broyl A, Corthals S, Jongen, J van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst H, Durie B, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. The Lancet Oncology. 2010;11(11):1057-1065. https://doi.org/10.3410/f.7619956.7925054
  58. Hershman D, Lacchetti C, Loprinzi C. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice. 2014;10(6):421-424. https://doi.org/10.1200/jop.2014.001776
  59. Smith E, Pang H, Cirrincione C, Fleishman S, Paskett E, Ahles T, Bressler L, Fadul C, Knox C, Le-Lindqwister N, Gilman P, Shapiro C, Alliance for Clinical Trials in Oncology. Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy. JAMA. 2013;309(13):1359. https://doi.org/10.1001/jama.2013.2813
  60. Franconi G, Manni L, Schröder S, Marchetti P, Robinson N. A Systematic Review of Experimental and Clinical Acupuncture in Chemotherapy-Induced Peripheral Neuropathy. Evidence-Based Complementary and Alternative Medicine. 2013;2013:1-7. https://doi.org/10.1155/2013/516916
  61. Marineo G, Iorno V, Gandini C, Moschini V, Smith T. Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline-Based Drug Management: Results of a Pilot, Randomized, Controlled Trial. Journal of Pain and Symptom Management. 2012;43(1):87-95. https://doi.org/10.1016/j.jpainsymman.2011.03.015
  62. Brunelli B, Gorson K. The use of complementary and alternative medicines by patients with peripheral neuropathy. Journal of the Neurological Sciences. 2004;218(1-2):59-66. https://doi.org/10.1016/j.jns.2003.10.013
  63. Speck R, DeMichele A, Farrar J, Hennessy S, Mao J, Stineman M, Barg, F. Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Supportive Care in Cancer. 2012;20(10):2433-2439. https://doi.org/10.1007/s00520-011-1365-8
  64. Holodova NB, Sotnikov VM, Dobrovol’skaja NYu, Pankratova YuA. Clinical characterictics and treatment of polyneuropathy developed after chemotherapy. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2013;113:5:20-24. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.